Although intratumor diversity driven by selection has been the prevailing view in cancer biology, recent population genetic analyses have been unable to reject the neutral interpretation. As the power to reject neutrality in tumors is often low, it will be desirable to have an alternative means to test selection directly. Here, we utilize gene expression data as a surrogate for functional significance in intra-and intertumor comparisons. The expression divergence between samples known to be driven by selection (e.g., between tumor and normal tissues) is always higher than the divergence between normal samples, which should be close to the neutral level of divergence. In contrast, the expression differentiation between regions of the same tumor, being lower than the neutral divergence, is incompatible with the hypothesis of selectively driven divergence. To further test the hypothesis of neutral evolution, we select a hepatocellular carcinoma tumor that has large intratumor SNV and CNV (single nucleotide variation and copy number variation, respectively) diversity. This tumor enables us to calibrate the level of expression divergence against that of genetic divergence. We observe that intratumor divergence in gene expression profile lags far behind genetic divergence, indicating insufficient phenotypic differences for selection to operate. All these expression analyses corroborate that natural selection does not operate effectively within tumors, supporting recent interpretations of within-tumor diversity. As the expected level of genetic diversity, hence the potential for drug resistance, would be much higher under neutrality than under selection, the issue is of both theoretical and clinical significance.
Introduction
Tumorigenesis is a form of evolution: Mutation and selection are the essential components of this process (Cairns 1975; Nowell 1976 ). In the prevailing view, the genetic heterogeneity in tumors was dictated by Darwinian selection, leading to the therapeutic failure in primary cancer types (Bozic et al. 2010; Marusyk and Polyak 2010; Gerlinger et al. 2012; Bedard et al. 2013; Burrell et al. 2013; Landau et al. 2013; Sottoriva et al. 2013; de Bruin et al. 2014; Wang et al. 2014; Zhang et al. 2014) ; whereas the theory of population genetics predicts a wealth of clonal diversity that is adaptively neutral and functionally irrelevant, leaving little functional heterogeneity within populations (Kimura 1983; Hartl et al. 1997; Ewens 2004) . By performing high-density sampling within tumors and testing whether an alternative non-Darwinian model may account for the high level of intratumor genetic heterogeneity, the non-Darwinian forces were proposed to contribute to the number of mutations in the entire tumor, implying that mutations within a tumor are not necessarily relevant to changes in cell fitness Sottoriva et al. 2015) . The non-Darwinian process, however, may not accurately characterize the evolution between tumor and nontumor tissues, or between different tumors in the same individual . When the patterns of genetic diversity within and between natural populations (or species) are different, the differences are often connected to functional divergence between populations (McDonald and Kreitman 1991; Fay et al. 2002; Shapiro et al. 2007) . As it suggests, the source of within-patient functional heterogeneity might be between different tumors, rather than within the same tumors. The selectivity of the genetic divergence within and between tumors for cellular fitness, which results in phenotypic variations, needs to be examined directly.
In the view of selectionism in cancer biology, there should be enough phenotypic divergence for selection to operate on (Bignell et al. 2010; Podlaha et al. 2012; Swanton 2012; Yates and Campbell 2012; Almendro et al. 2013; Burrell et al. 2013; Vogelstein et al. 2013; McGranahan et al. 2015; Tabassum and Polyak 2015) . Phenotypic changes in tumors may be represented by variation in transcriptome profiles. The mRNA level has been treated as the "intermediate phenotype" that links genetic variations to changes in physiological traits (Chesler et al. 2005; Hubner et al. 2005; Li et al. 2006) . Previous studies have shown that gene expression is a complex quantitative phenotype with variability among individuals or cell types (Cheung and Spielman 2002; Schadt et al. 2003; Bystrykh et al. 2005; Zhang et al. 2008) , which is important in evolution (Oleksiak et al. 2002) . In sexual populations, gene expression variation has a large trans-acting component, which is often difficult to be disentangled from the environmental influences (Williams et al. 2007; Wang et al. 2008) ; whereas in tumor cells that are asexual, the trans-acting component is faithfully transmitted. For that reason, the total genetic component of expression variation and the signal of natural selection in cell populations should be more easily measurable than in natural populations.
In this study, we use gene expression profile as the phenotype. The differences in the expression profile both within (multiple sections in a tumor; tt) and between (the paired primary and metastatic tumors; tt*) tumorous cell populations are measured, and compared with the expression divergence between paired tumor and nontumor tissues (nt) driven by selection, and the divergence between the normal tissues (NN). The level of genetic distance between NN represents the polymorphisms in human population, which are prevalently neutral, associated with little phenotypic difference in fitness (Kimura 1983; Hartl et al. 1997) ; whereas, in the measurement of nt, the tumors have accumulated a number of functional mutations which are responsible for many phenotypic changes in cell fitness when evolving from normal tissues during the tumorigenesis (Hanahan and Weinberg 2011) . Therefore, the difference in gene expression between normal and tumor tissues is expected to be larger than the expression difference that has been resulted from neutral divergence of NN. In relation to the NN, the tt and tt* could be the same as nt or the opposite, which is determined by whether the polymorphisms within tumors contain functional mutations or not.
In addition, to examine how much the lineage-specific mutations (specific to a certain subclone within a tumor) contribute to the changes in cellular advantages among subclones, the variations in both levels of genetics and gene expression for the subclones must be characterized. Considering that the variations in expression are of less possibility to be detected between clones with small number of mutations, we carry out genomic and RNA sequencing in multiple sections from a hepatocellular carcinoma (HCC) tumor in which the highest genetic divergence between subclones was detected among a dozen of HCC patients in a previous study . The transcriptional difference between multiple tumor sections is comparable to that between three adjacent nontumor samples in which no genetic and phenotypic variation exist. Whether intra-and intertumor genetic diversity may or may not lead to phenotypic/transcriptional difference is addressed.
Results

Transcriptome Diversity within and between Tumors
To examine how much, in general, transcriptional heterogeneity exists within a tumor, we analyze the published transcriptional data and calculate the correlation of gene expression between different sections within tumors. The gene expression profiles of various sections within tumors and their parallel adjacent nontumor tissues were interrogated in ten glioblastoma multiforme (GB) patients (Sottoriva et al. 2013 ) and ten clear cell renal cell carcinoma (ccRCC) patients measured by Illumina HumanV4.0 and Affimetrix HuGene microarrays, respectively (Gerlinger et al. 2012 (Gerlinger et al. , 2014 . Multiple (4-9) sections in each tumor and the matched normal tissue were profiled in an individual. In total, we investigate microarray expression profiles for 50 and 60 tumor sections in GB and ccRCC, respectively.
From the expression data, we calculate the Spearman correlation coefficient (q) between 1) normal tissues of different individuals (NN), 2) tumors of different individuals (TT), 3) matched normal and tumor tissues in an individual (nt), 4) different samples of the same tumor (tt), and 5) paired primary and metastatic tumors of the same individual (tt*). Note that NN and TT comparisons include the background divergence between individuals whereas nt, tt, and tt* are measurements within the same individual. The box-andwhisker diagrams of q are illustrated in figure 1A and B where the dotted line separates the NN and TT comparisons from the nn, tt, and tt* measurements. The median values of the correlation coefficients, standard deviations (SDs), and the first and third quartiles are shown in supplementary table S1, Supplementary Material online.
The baseline for all comparisons is the level of expression variation affected by the neutral background genomic variation in the germ line among individuals, which is the NN measurement. Variation in gene expression among tumors of different individuals (TT) is greater (lower q) than the NN ( fig. 1 , supplementary tables S1 and S2, Supplementary Material online), which is expected as each tumor has been driven by different selective pressure during its evolution. The expression divergence between matched normal and tumor tissues (nt) is the greatest, with the median q at 0.82 for GB and 0.80 for ccRCC. This comparison is most informative because the nt divergence happens within the same individual without the background germ line divergence.
It is interesting to note that the intratumor divergence (tt) shows the highest correlation coefficients with a median value of 0.92 for both GB and ccRCC ( fig. 1 (Enard et al. 2002; Khaitovich et al. 2005; Pastinen et al. 2006; Storey et al. 2007; Hughes et al. 2015) . To eliminate the interindividual phenotypic difference that is plausibly driven by diversifying and directional selection, genes that are significantly differently expressed between normal samples (approximately top 10% of highly variable genes) are excluded in the adjusted calculation of correlation in NN. The correlation of tt is still significantly higher than the adjusted median q of NN (q adj ) for GB (P ¼ 3.3e-15, KS test), and not significantly deviated from the q adj for ccRCC (P ¼ 0.09, KS test; supplementary fig. S1 and table S2, Supplementary Material online).
We further compare the paired primary tumor and metastases (or relapses) within the same individual (tt*). The gene expression data from both primary tumor sections and metastatic tumors are available in the ccRCC study (Gerlinger et al. 2012) . The amounts of expression variations between matched primary and metastatic tumors (tt*) are evaluated by comparing them to the correlation of gene expression of NN and tt. The median q of tt* in ccRCC is 0.88, which is lower than the medians of NN and tt (fig. 1B, supplementary tables S1 and S2, Supplementary Material online) . We additionally analyze RNA-Seq data from 111 pairs of breast normal and tumor samples as well as seven pairs of primary and metastatic tumors from the TCGA database, and calculate the q for NN, TT, nt, and tt*. Compared with the NN, relatively lower similarity in expression between primary and metastatic tumors is also observed in breast cancer (BRCA) samples ( fig. 1C ).
Mutations Driving Expression Divergence
The analysis above suggests that cancer-driving mutations are responsible for the expression divergence in nt comparisons. May such mutations also be found in tt* pairs but be largely absent in the tt comparisons ( fig. 2A and B) Lawrence et al. 2013; Vogelstein et al. 2013; Wu et al. 2016) . Figure 2B is the approximate expression difference. The functional mutations in the evolution of N into T affect phenotypic changes in cell proliferation, apoptosis, and so on (Hanahan and Weinberg 2011) , leading to thousands of differently expressed genes and a large d nt (Hofree et al. 2013; Babur et al. 2015; Liang et al. 2015 ; see the third section of the Results). However, the expected expression distances between intratumor subclones (d tt ) could be either larger or smaller than d NN under the assumptions of the presence or absence of functional mutations during intratumor divergence, respectively.
The estimated d nt is >3 times larger than the divergence (d NN ) resulted from neural polymorphisms in all types of cancers ( fig. 2C ). It is consistent with the expectation that the effect of mutations in the evolution of normal into tumor cells is substantial, resulting in large expression divergence. Whereas, we observe that the d tt is less than the half of the d NN . When the speed and extent of divergence are not higher than the neutral background, selection is either absent or too weak to make a difference (Kimura 1983; Nei 1987) . Therefore, the observation does not indicate selection within tumors. 
MBE
It has been reported that the expression patterns of metastatic activities or specific gene expression signatures markedly differ between primary tumors and metastases (Riker et al. 2008; Malek et al. 2012) . Concordantly, the distance between the primary and metastases (d tt* ) is higher than d NN and d tt , indicating that functional divergence may emerge more frequently between discrete tumors than within a tumor. According to the Gene Ontology (GO) analysis, the 58 genes that are expressed differentially between breast primary and metastatic tumors are overrepresented in the processes related to the regulation of cell migration and mobility, cell activity, adhesion, and differentiation (supplementary tables S3 and S4, Supplementary Material online).
Transcriptome Diversity in Relation to Genetic Diversity within an HCC Tumor
To address whether the subclone-specific mutations may be of selective advantage of changing the phenotypic fitness of a subclone, it is indispensible to investigate both the genetic alterations and the variations in gene transcription in different sections in a tumor. A highest ratio of genetic difference between subclones within tumors against the difference between normal and tumor tissues was observed in one of HCC Test of Functional Divergence within and between Tumors . doi:10.1093/molbev/msx115 MBE cases by Tao et al. (2015) . In this study, three (T A1 , T B2 , and T C1 ) of 12 tumorous tissue sections and adjacent nontumor tissue (N) are further utilized for detection and validation of variations at DNA and RNA levels (supplementary tables S5 and S6, Supplementary Material online). Somatic single nucleotide variants (SNVs) and copy number alterations (CNAs) are both taken into account. The control samples used in the comparison are the three adjacent nontumor tissue sections, which have no phenotypic and germ line genetic variations.
Sixty-five SNVs, including 54 nonsynonymous and 11 synonymous somatic mutations, are identified in the HCC tumor with three well-demarcated nodules (T A , T B , and T C ; fig. 3A ) and validated in the 12 tumor sections (supplementary tables S5 and S7, Supplementary Material online). Three nodules of the tumor are clonal and shared 31 SNVs in the coding region. The phylogenetic analysis of the tumor reveals a branching pattern with four distinct subclones (Ta, Tb, Tb 0 , and Tc), which are distinguished by 23 lineage-specific SNVs ( fig. 3A and supplementary table S7, Supplementary Material online). The phylogenetic tree shows that the cancer cells within the tumor are highly genetically heterogeneous. The divergence between the most divergent subclones (Ta and Tb 0 ) is as large as 71% (22/31) of the difference between the tumor and nontumor tissues.
We subsequently identify the chromosomal CNAs for each chromosomal segment according to the read depth revealed by whole-genome sequencing. Compared with N 1 , majority of the chromosomes are subject to copy number gain and loss or LOH (loss of heterozygosity) in the tumor, and eight chromosomal CNAs on chromosomes 1, 4, 6, 16 and X are commonly shared by all three nodules (T A , T B , and T C ) (supplementary fig.  S2 , Supplementary Material online). Because Ta and Tb 0 are the most divergent subclones within this tumor based on the SNV data, we focus on investigating the intratumor differences in CNAs between Ta and Tb 0 with tissue sections of T A1 and T B2 based on exome-sequencing data. The ploidy of the chromosomes estimated by R package Sequenza (Favero et al. 2015 , http://www.cbs.dtu.dk/biotools/sequenza/; last accessed April 3, 2017) is either triploid or tetraploid in T A1 and T B2 ( fig.  3B ), supporting the finding that chromosomal gains have been frequently observed in human cancers including HCCs (Carter et al. 2012) , except that chromosome 10 in T A1 and chromosome 13 in T B2 are typical diploid. Chromosomes 1p, 4q, 6q, and 16 are subject to LOH in both T A1 and T B2 . The chromosomal ploidy in T A1 significantly deviates from T B2 by 12 chromosomal CNAs (labeled on the top of fig. 3B ).
To address whether the divergence of gene transcription between subclones is as large as the diversity revealed by SNVs and CNAs, we carry out RNA-Seq for three sections (T A1 , T B1 , and T B2 ) in the two larger nodules (T A and T B ). Additionally, the differences between tumor sections are compared with those between three adjacent nontumor sections (N 1 , N 3 , and N 5 ). The scatter plot for the pairwise comparison of gene expression shows that the Pearson correlation coefficients between intratumor sections (0.928, 0.964, and 0.984) are much higher than those between tumor and nontumor tissues (0.791), but close to the correlations among three normal replicates (0.977, 0.993, and 0.986) (table 1 and supplementary fig. S3, Supplementary Material online) . The number of differentially expressed genes (DEGs) between tumor and nontumor tissues is $30 times more than that between the tumor sections, no matter which of the two criteria is used to filter the DEGs (table 1 and supplementary  table S8 , Supplementary Material online). The number of DEGs between T A1 and T B2 , which represent the two most divergent subclones Ta and Tb 0 , is 3% of that between tumor and nontumor tissues, whereas the number of genetic differences between Ta and Tb 0 is 71% (22/31) of the difference between tumor and normal tissues (table 1) .
The transcriptional differences between subclones are significantly and disproportionately lower than their genetic diversity compared with the difference between the tumor and nontumor sections, indicating that the effect of lineagespecific SNVs on the differences between subclones in gene expression is much smaller than that of mutations on the trunk. The DEGs between tumor and normal tissues are enriched in cell cycle (upregulated in tumor tissues) and immunity (downregulated in tumor tissues) processes (supplementary table S9, Supplementary Material online), which are related to the hallmarks of tumorigenesis (Hanahan and Weinberg 2011) .
Because the amplification and deletion of large genomic segments might have stronger impact on gene expression changes than the point mutations of specific genes, we further investigate the effects of chromosomal CNAs on the gene expression. The expression levels of genes on chromosomes or chromosomal arms with CNAs in tumor sections significantly differ from the expression levels in adjacent nontumor sections (KS test, P < 0.05; fig. 3C and supplementary fig. S4, Supplementary Material online) . On the contrary, the gene expression presents no difference (P > 0.05) between T A1 and T B2 , despite the extensive intratumor CNAs ( fig. 3C and supplementary fig. S4 , Supplementary Material online). The high heterogeneity in chromosomal CNAs does not lead to large transcriptional changes within the tumor. The tumor with highly genetic heterogeneity is essentially homogeneous at transcriptional level.
Discussion
The theory of clonal evolution states that cancers arise from a single cell and genetically diverge to disparate cell subclones and successive clones during cancer cell replications (Nowell 1976) . In the evolution of normal cells into cancer cells, cells acquire the hallmarks of cancer through somatic mutation and selection (Cairns 1975; Hanahan and Weinberg 2011) . The majority of somatic mutations with functional implications for tumorigenesis (the "drivers") throughout the genome are usually shared by all tumor cells in most of tumors as detected in TCGA projects (Kandoth et al. 2013; Vogelstein et al. 2013; Martincorena and Campbell 2015) . In this study, we observe that divergence in gene expression between matched tumor and normal tissues is the highest among the comparisons, which is consistent with the notion that cancer cells have been subject to phenotypic change in cellular fitness in tumorigenesis (Bignell et Burrell et al. 2013; Vogelstein et al. 2013; Babur et al. 2015; Liang et al. 2015) .
Intratumor heterogeneity caused by the accumulation of additional mutations in subclones during tumor evolution has been recognized for decades at the cell morphological, protein and genetic levels (Frierson 1993; Weigelt and ReisFilho 2009; Gerlinger et al. 2012 Gerlinger et al. , 2014 Swanton 2012 ). In the model of selection, the logical extrapolation of these intratumor genomic variations predicts the possibility of significant heterogeneity in gene expression within a tumor. However, based on the analysis of published data in various types of cancers in this study, the difference at the transcription level within a tumor is lower than the neutral background divergence between normal tissues. Selection is not suggested. Nevertheless, to assess the clinical relevance of the intratumor genetic heterogeneity, it is necessary to quantitatively evaluate the degree to which the changes in copy numbers and nonsynonymous mutations will cause alterations in gene expression and phenotypes. Therefore, genome-wide studies of intratumor heterogeneity at both the genomic and transcriptional levels that utilize a spatial multisampling strategy within an individual tumor mass are required. We herein profile the whole-exome point mutations, chromosomal CNAs, and whole transcriptional differences of spatially defined multiple sections within an HCC tumor and multiple sections within each tumor nodule. Different sections within this tumor are relatively homogeneous at the transcriptional level despite their immense genetic divergence. In the HCC tumor, the mutant genes involved in DNA repair and cell cycle categories are present on the trunk rather than on the branches of the phylogenetic tree, based on the GO analysis (supplementary table S10, Supplementary Material online). If the subclone-specific mutations are of functional insignificance, in other words, selectively neutral, the gene expression profiles and the phenotypic fitness may be not affected. The results, apparently, do not support that the intratumor genetic diversity is driven by selection. Given the prevalence of passenger mutations, the subclones could be delineated by functionally irrelevant mutations.
An alternative explanation for the observation that the expression differentiation within tumors is lower than the neutral divergence is the purifying selection in the evolution within tumors. Natural selection can be positive (for the beneficial mutations) or negative/purifying (against the deleterious ones). Little attention has been paid on the power of negative selection in cancer evolution. Wu et al. (2016) reported the average Ka/Ks ratio of 1 on all genes and the exceeding percentage of negative sites in comparison with the simulated distribution, suggesting that the possibility of negative selection operating on the genes with essential function of cells should not be ignored. The operation results in stabilizing selection through the purging of deleterious variations that arise, eventually reducing the variation in phenotypes in populations. In the case of cancer cell population without recombination, the effect of negative selection could be high, as the purging of deleterious variants will result in the removal of linked variation (Kondrashov 1988; Hudson and Kaplan 1995) . The evolutionary forces and exploration of the effect and genes under selection remain to be tested.
As the indication of neutral model on the genetic diversity within populations, the genetic heterogeneity within tumors is not necessarily expected to result in significantly functional differences between cancer cells at the gene expression level Sottoriva et al. 2015; Tao et al. 2015) . Whereas, we reveal that the phenotypic difference is higher between discrete cancer cell populations/tumors than that within a tumor. Genetic variations in metastases and recurrent tumors due to the selection pressure of treatment may be more associated with increased migration and growth than the primary tumor in an individual. Divergent expression profiles in the tumors presumably with distinct phenotypic properties have been observed between the primary tumors and the metastatic tumors as well as among multifocal tumors (Bachtiary et al. 2006; Bashashati et al. 2013; Sottoriva et al. 2013; Gerlinger et al. 2014) . In ccRCCs and ovarian cancers, the mutations that had significantly impacted the expression networks were only detected between discrete tumors in the same organ or between the primary and metastatic tumors (Bashashati et al. 2013; Gerlinger et al. 2014 ). Selection appears to possibly play a much pivotal role between primary and metastatic tumors in different organs and between multifocal tumors that scatter throughout discrete spaces in the same organ than within tumors (Nguyen et al. 2009; Valastyan and Weinberg 2011; Klein 2013; Zhang et al. 2013; Gundem et al. 2015; Tao et al. 2015) . The simplest argument for selection is that the metastases often started to grow much later than the primary tumor but often become larger than the primary in a shorter period of time . Further surveys with intensive microdissection within a tumor tissue as well as paired primary and metastatic tumors are required to understand the contributions of cellular nonstochastic variations to the fitness of subclones (even with a diminutive volume in primary tumors), to metastasis and relapse, as well as to the correlation between phenotypic variations and genetic diversity.
Materials and Methods
Transcriptional Data in Various Cancer Types
To assess the intratumor heterogeneity, we downloaded the Illumina HT12v4 expression array data in 50 tumor sections and nine adjacent normal tissues (right panel) . Genes on all the chromosomes with copy number differentiations between the compared samples were included when plotting the cumulative distributions. The P values are derived from the KS test. Li et al. . doi:10.1093/molbev/msx115 MBE in ten glioblastoma patients (Sottoriva et al. 2013 ; http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-1129/; last accessed April 3, 2017), and the Affymetrix HuGene-1_0-stv1 expression array data in 60 primary tumor samples and six normal samples from 10 ccRCC patients (Gerlinger et al. 2014 ; http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-53000/, last accessed April 3, 2017; Gerlinger et al. 2012 ; http:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc¼GSE31610; last accessed April 3, 2017). In each tumor tissue, 4-9 sections were dissected and profiled. To investigate the transcriptional difference between primary and metastatic tumors, we downloaded the microarray data in seven primary ccRCC tumor samples and two chestwall metastatic samples (Gerlinger et al. 2012 ; http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc¼GSE31610; last accessed April 3, 2017), as well as the RNA-Seq data in seven pairs of primary and metastatic tumors from BRCA patients in the TCGA database (https://tcga-data.nci.nih.gov/ docs/publications/tcga/; last accessed April 3, 2017). Additionally, 111 pairs of breast normal and tumor samples were obtained for comparison (https://tcga-data.nci.nih.-gov/docs/publications/tcga/; last accessed April 3, 2017).
Gene Expression Analyses for the Published Transcriptional Data
To calibrate the gene expression profiles from the Illumina HT12v4 and Affymetrix HuGene-1_0-st-v1 data, we selected the probes that can be perfectly matched to genes and condensed the "multiple-probes-to-one-gene" expression pattern to a "one-probe-to-one-gene" pattern by randomly selecting one probe to represent the entire gene based on the method described in the original paper (Sottoriva et al. 2013 
Estimation of Correlation Coefficients between Compared Transcriptional Profiles
We calculated the Spearman correlation coefficient (q) between intratumor sections (tt), between primary and metastatic tumors (tt*), between tumors of different individuals (TT), between the same type of normal tissues in different individuals (NN), as well as between matched normal and tumor tissues in an individual (nt). Genes that are not or lowly expressed in both compared samples were excluded in the calculation of q. For RNA-Seq data analysis in the HCC case (see below), genes with RPKM (reads per kilobase of exon model per million mapped reads) <1 were considered as not or lowly expressed. To remain the consistency, for the other kinds of expression data, the bottom 35% genes in ranking from high to low expression were filtered out in comparisons (supplementary fig. S5, Supplementary  Material online) . The relative distributions of q among the comparisons were not affected by different filtering criteria Test of Functional Divergence within and between Tumors . doi:10.1093/molbev/msx115 MBE (supplementary fig. S6, Supplementary Material online) . The significant tests for q between comparisons were performed using a nonparametric test namely KS test. The calculation of Bonferroni-adjusted P-values was employed to correct for multiple comparisons.
Adjusted Spearman Correlation Coefficient of NN
For the highly variable genes in gene expression between individuals are more likely to contribute to the interindividual phenotypic difference that is plausibly driven by diversifying and directional selection than the lowly variable ones, we recalculated the Spearman correlation of gene expression between NN after eliminating the genes with highly interindividual variation in expression. The gene expression data of the normal tissues in the data sets of ccRCC and GB were firstly normalized by performing limma (Ritchie et al. 2015) and oligo (Carvalho and Irizarry 2010) programs, respectively. Using the normalized gene expression, we calculated the coefficient of variation (CV) of expression for each gene between NN, which is used as the conventional measurement of expression variability. Nevertheless, the CV noticeably induces a very strong bias toward lowly expressed genes (supplementary fig. S7 , Supplementary Material online), which represents an adverse statistic to measure the gene-wise expression variability (Alemu et al. 2014 ). Subsequently, we investigated the SD against overall mean of gene expression on original and log2 scales, respectively, to determine the most optimal models to interpret the relationships (supplementary fig. S7 , Supplementary Material online). As implied in supplementary figure S7 , Supplementary Material online, the SD increases linearly with the mean of gene expression on log2 scale, which is congruent with the property of Gamma distribution. Therefore, we used quasi-likelihood to model the variance as a function of mean expression for each gene, beneath the assumptions of a gamma-distributed variance with link function modeled as logarithm (McCullagh and Nelder 1989) . We next estimated the standardized deviance residual (normally distributed with mean ¼ 0 and variance ¼ 1) for each gene and sample based on the fitted model, where, the genes with at least one significantly deviated residual at the statistically significant level of 0.01 (>2.58 or < À2.58) were regarded as the genes with high variation between individuals (supplementary fig. S8 , Supplementary Material online). After removing the highly variable genes, we recalculated the Spearman correlation between NN as the adjusted q of NN (q adj ). The genes that are not expressed or lowly expressed were excluded in this calculation.
Distance between Compared Transcriptional Profiles
The Illumina HT12v4 expression array data for GB and the Affymetrix HuGene-1_0-st-v1 expression array data for ccRCC were normalized by performing limma (Ritchie et al. 2015) and oligo (Carvalho and Irizarry 2010) programs, respectively. For the RNA-Seq data in BRCA, the RSEM values that have been already normalized were directly used for the calculation. The pairwise distance (d ij ) between expression profiles in given comparisons (NN, nt, tt, tt*) for GB, ccRCC, and BRCA was determined by summing up the absolute gene expression ratios on log2 scale of the included genes (Enard et al. 2002) .
where n is the number of included genes, x i g is the normalized expression of gene g measured in sample i and x j g in sample j. The distances between expression profiles in given comparisons (d NN ; d nt ; d tt ; d ttÃ ) were determined as the medians of the pairwise distances. Genes that are not or lowly expressed in both compared samples were excluded in the calculation. Only those differently expressed genes that showed the fold change greater than 2 between compared samples were considered. The distances were shown in figure 2C and supplementary table S11, Supplementary Material online.
Identification of Genes Differentially Expressed between Primary and Metastatic Tumors
The DEGs in each pair of breast primary and metastatic tumors were obtained by performing DESeq package (Version 1.14.0). Stringent filter criteria with adjusted P < 0.01 and fold-change ! 2 were applied. The DEGs that were observed in at least two breast tumor patients were used in GO analysis (supplementary table S3, Supplementary Material online).
HCC Patient and Tissue Samples
The liver tissue was surgically resected from a 63-year-old woman with HBV-related liver cirrhosis. The tumor was 4 Â 2.5 Â 2 cm and located in the right lobe of the liver; it was featured by three well-demarcated nodules (T A , T B , and T C ). Four (T A1-4 ), seven (T B1-7 ), and one (T C1 ) sections were removed from nodules T A , T B , and T C , respectively. Three sections (N 1 , N 3 , and N 5 ) were collected in the adjacent nontumor tissue. All tissue samples were stored in RNA later (Ambion, Austin, TX) at À80 C before being used for DNA or RNA extraction ( fig. 3 and supplementary 
Whole-Genome Sequencing Library Construction
Genomic DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). Out of the sections, three tumorous samples and one adjacent normal sample were previously exome sequenced by Tao et al. (2015) . Herein, the same samples were further utilized for whole-genome sequencing. The genomic DNA (3 mg) was fragmented by Adaptive Focused Acoustics on a Covaris E120 (Covaris Inc, Woburn, MA). The fragmented DNA was purified using a Qiaquick PCR purification column and quantified on a 2100 Bioanalyzer using the Agilent DNA 1000 kit. DNA fragments concentrated between the 200-and 300-bp bands. Library construction was performed using the Agilent SureSelect kit without exome-enrichment for the Illumina single-end sequencing platform (Agilent, Santa Clara, CA) according to the manufacturer's instructions, which was Li et al. . doi:10.1093/molbev/msx115 MBE further used for whole-genome sequencing on a HiSeq 2000 (Illumina). The raw sequencing reads are available in the Sequence Read Archive (SRA) under the accession number of SRP054252. The statistical data for whole-genome sequencing, as well as the summary for previous exome sequencing, are provided in supplementary table S6, Supplementary Material online.
SNV Detection and Validation
Single-end reads of exome sequencing generated with an Illumina GAIIx (for N 1 , T A1 , and T B2 ) or HiSeq 2000 (for T C1 ) were mapped to a human genome reference (hg19) using BWA (Version 0.4.9) with default parameters ). The PCR (polymerase chain reaction) duplication reads were removed using SAMtools (Version 0.1.7) ). SNVs were called using VarScan 2 (Version 2.2) for uniquely mapped reads and default parameters (Koboldt et al. 2012) . The candidate SNVs were further filtered using the following criteria: 1) The read depth of the SNV sites for both tumor and nontumor sections was at least 10, 2) at least three reads supporting mutant alleles were required in the tumor sections, 3) less than two reads of mutant alleles were detected in the normal section, and 4) only the SNVs supported by more than two reads in both the forward and the reverse strands were claimed for the T C1 section, which was uniquely sequenced on Illumina HiSeq 2000 platform.
The candidate somatic SNVs were validated using a Sequenom MassArray (Sequenom, San Diego, CA) in all of the 12 tumorous sections and the adjacent normal section. The genomic positions of all SNVs were retrieved using the hg19 build. PCR and MassEXTEND primers for multiplexed assays were designed by the Sequenom MassARRAY Assay Design 3.1 software. The MassEXTEND reaction and iPLEX Gold assay were carried out for primer extension and SNV allele detection. The mutation calls and allele frequencies for each SNV site were determined using a MassArray Typer 4.0 Analyzer according to the manufacturer's instructions. The information of the validated SNVs is given in supplementary table S7, Supplementary Material online.
Chromosomal CNAs Detection by Both WholeGenome and Exome Sequencing Data
The whole-genome sequencing reads of N 1 , T A1 , and T B2 were mapped to hg19 using BWA (Version 0.4.9) with default parameters ). CNV-seq was subsequently employed to calculate the normalized log 2 ratio of read depths between tumor and normal sections (Xie and Tammi 2009 ). DNAcopy (Version 1.40.0) was employed to segment the CNA regions based on the normalized log 2 ratio using a circular binary segmentation algorithm (Venkatraman and Olshen 2007) . Nevertheless, the purity of cancer cells interferes with the identification of CNAs. We estimated the purity of each tumor section based on the identified three LOH regions (chr16, chr6p, and chrX), which were inferred by combining the initial CNA regions and the B allele frequencies of identified SNPs (single nucleotide polymorphisms). The purity, which was equivalent to twice of the median of SNP frequency in the LOH regions, was estimated as 0.825 for T A1 , 0.765 for T B1 , and 0.52 for T C1 , respectively. Based on the estimated purity, the threshold of log 2 ratio for claiming a one-copy-loss was corrected as following: À0.333 (T A1 ), À0.302 (T B2 ), and À0.201 (T C1 ) based on the formula (purity Â 1 þ (1 À purity)Â2)/2. The threshold of log 2 ratio for claiming a one-copy-gain was corrected as following: 0.271 (T A1 ), 0.252 (T B2 ), and 0.176 (T C1 ) based on the formula (purity Â 3 þ (1 À purity)Â2)/2. The chromosomal copy number variations estimated by whole-genome sequencing data are illustrated in supplementary figure S2, Supplementary Material online.
We used the R package Sequenza (Favero et al. 2015) to quantify the cancer cell purity and genome-wide chromosomal alteration based on the exome sequencing data of N 1 , T A1 , and T B2 . The copy number changes can be more precisely estimated by integrating the information on the cancer cell purity, allele frequency, and read depth rather than only on the read depth for low-coverage wholegenome sequencing. The SNP sites and copy-number information were derived from the "somatic" and "copynumber" programs of the VarScan 2 suite (Version 2.3.6), which were subsequently converted by VarScan2seqz into the seqz format required by Sequenza. The depth ratios were normalized according to the GC content. Based on the calculated B allele frequency and normalized depth ratio, the purity and ploidy were inferred from the point estimates with the maximum log posterior probability by fitting a Sequenza model. The allelic copy numbers of chromosomal segments were further inferred by Sequenza according to the estimated purity (T A1 : 0.825, T B2 : 0.765) and ploidy (T A1 : 3, T B2 : 3.4).
RNA-Seq Library Construction
Frozen tissue samples ($10 mg/sampled section) were ground with a pestle and cordless motor (Kontes) and extracted using TRIZOL reagent (Invitrogen). The mRNA was purified from 10 lg of total RNA using the FastTrack MAG mRNA Isolation Kits (Invitrogen). The purified mRNA was fragmented by RNase III (Ambion) at 37 C for 90 s. The fragmented mRNA samples were further purified with the RiboMinus Concentration Module (Invitrogen) and subjected to ligation with adapters, reverse transcription, cDNA purification, and PCR using the SOLiD Small RNA Analysis Kit (Ambion) according to the manufacturer's instructions. The yield and size distribution of the amplified DNA were analyzed with a 2100 Bioanalyzer (Agilent, Waldbronn, Germany), and the amplified DNA was size-selected in the range of 100-200 bp for SOLiD sequencing. Emulsion PCR and SOLiD sequencing were performed according to the Applied Biosystems SOLiD System manufacturer's instructions (Applied Biosystems, Foster City, CA) for wholetranscriptome sequencing. The raw sequenced reads have been submitted to SRA under the accession number of SRP054252. The statistics of RNA-Seq data are in supplementary table S6, Supplementary Material online.
Gene Expression Analysis
The SOLiD (v3.0 or 3.5) sequencing reads were analyzed using the BioScope Software provided by Applied Biosystems.
Test of Functional Divergence within and between Tumors . doi:10.1093/molbev/msx115 MBE Reads mapped to adapters, ribosomal RNAs, and transfer RNAs, were excluded from further analysis. The remaining reads were mapped to hg19. The aligned reads were annotated based on the UCSC refGene and Ensembl database. Only uniquely mapped reads located in exon or exonintron junction regions were used to calculate RPKM for each gene using the standard formula:
where C is the number of uniquely mapped reads in the merged exon regions, N is the total number of unique mapped reads, and L is the length of the exons (Mortazavi et al. 2008 figure S3 , Supplementary Material online, was also generated with the DESeq package. The correlation of gene expression level was described using Pearson correlation coefficient. The mean expression values in three tumor sections and three normal replicates were calculated to estimate the correlation between tumor and normal tissues. Genes that were not expressed or lowly expressed (with RPKM < 1) in both of the two compared samples were not included in the analysis.
Cumulative Distributions of Gene Expression across Chromosomal CNA Regions
The empirical cumulative distributions of gene expression profiled by the RPKM values on log 2 scale were plotted using R package for the compared tissue sections, between T A1 and N 1 , T B2 and N 1 , and T A1 and T B2 . The cumulative distributions of gene expression on each chromosome or chromosomal arm were illustrated in supplementary figure S4, Supplementary Material online. As most of the chromosomes or chromosomal arms presented copy number gain in tumor sections (T A1 and T B2 ), the expression levels of all genes in these chromosomal regions were aggregated and profiled together in figure 3C . We explored the KS test to calibrate the influence of chromosomal CNAs on the gene expression. The corresponding P values were calculated with the KS test. Genes that were not or lowly expressed (with RPKM < 1) in the compared samples were ruled out in the KS test.
Supplementary Material
Supplementary data are available at Molecular Biology and Evolution online.
